Stockreport

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]

Kineta, Inc.  (KA) 
PDF No dose limiting toxicities observed at any dose level in the VISTA-101 trial Cleared fifth of six monotherapy cohorts and second of four combination cohorts in the V [Read more]